HUT65302A - Azaquinoxaline- derivatives with antiviral effect and process for the production of these compounds and of pharmaceutical preparatives containing it - Google Patents
Azaquinoxaline- derivatives with antiviral effect and process for the production of these compounds and of pharmaceutical preparatives containing it Download PDFInfo
- Publication number
- HUT65302A HUT65302A HU9302696A HU9302696A HUT65302A HU T65302 A HUT65302 A HU T65302A HU 9302696 A HU9302696 A HU 9302696A HU 9302696 A HU9302696 A HU 9302696A HU T65302 A HUT65302 A HU T65302A
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- alkoxy
- hydroxy
- amino
- chloro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 109
- 238000000034 method Methods 0.000 title claims description 24
- 238000004519 manufacturing process Methods 0.000 title description 3
- 230000000840 anti-viral effect Effects 0.000 title description 2
- 229910052720 vanadium Inorganic materials 0.000 claims abstract description 46
- 229910052721 tungsten Inorganic materials 0.000 claims abstract description 43
- 229910052727 yttrium Inorganic materials 0.000 claims abstract description 43
- -1 trifluoromethoxy, hydroxy, mercapto Chemical class 0.000 claims description 303
- 125000003545 alkoxy group Chemical group 0.000 claims description 120
- 125000001153 fluoro group Chemical group F* 0.000 claims description 119
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 100
- 125000000217 alkyl group Chemical group 0.000 claims description 94
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 92
- 125000003282 alkyl amino group Chemical group 0.000 claims description 67
- 125000004414 alkyl thio group Chemical group 0.000 claims description 65
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 65
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 64
- 125000004423 acyloxy group Chemical group 0.000 claims description 56
- 229910052739 hydrogen Inorganic materials 0.000 claims description 53
- 239000001257 hydrogen Substances 0.000 claims description 53
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 52
- 125000004043 oxo group Chemical group O=* 0.000 claims description 51
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 45
- 125000001246 bromo group Chemical group Br* 0.000 claims description 44
- 238000002360 preparation method Methods 0.000 claims description 44
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 43
- 125000002346 iodo group Chemical group I* 0.000 claims description 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 37
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 37
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 36
- 229910052801 chlorine Inorganic materials 0.000 claims description 35
- 239000000460 chlorine Substances 0.000 claims description 33
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 229910052731 fluorine Inorganic materials 0.000 claims description 27
- 239000011737 fluorine Substances 0.000 claims description 27
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 27
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 26
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 24
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 229910052794 bromium Inorganic materials 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 18
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 18
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 17
- 125000004442 acylamino group Chemical group 0.000 claims description 16
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 16
- 150000002431 hydrogen Chemical group 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000011593 sulfur Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 8
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 125000001769 aryl amino group Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 7
- 125000003107 substituted aryl group Chemical group 0.000 claims description 7
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 7
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 6
- 125000005110 aryl thio group Chemical group 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 5
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 5
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 5
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 claims description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims description 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 3
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical group CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 125000006323 alkenyl amino group Chemical group 0.000 claims description 3
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims description 3
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 3
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims description 3
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 150000002829 nitrogen Chemical class 0.000 claims description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 3
- 229910052711 selenium Chemical group 0.000 claims description 3
- 239000011669 selenium Chemical group 0.000 claims description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 3
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 229950005228 bromoform Drugs 0.000 claims description 2
- 150000001728 carbonyl compounds Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 125000001326 naphthylalkyl group Chemical group 0.000 claims description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 125000005108 alkenylthio group Chemical group 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 40
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 31
- 238000002844 melting Methods 0.000 description 31
- 230000008018 melting Effects 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 239000000741 silica gel Substances 0.000 description 23
- 229910002027 silica gel Inorganic materials 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 8
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 7
- 229910000564 Raney nickel Inorganic materials 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WZCKOKPKQZIGNU-UHFFFAOYSA-N 1h-naphthalen-2-one Chemical compound C1=CC=C2C=CC(=O)CC2=C1 WZCKOKPKQZIGNU-UHFFFAOYSA-N 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 3
- 229910001863 barium hydroxide Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 150000002391 heterocyclic compounds Chemical class 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 3
- 150000003195 pteridines Chemical class 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000011150 stannous chloride Nutrition 0.000 description 3
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 2
- QINVNYOGWDNSEP-UHFFFAOYSA-N 1h-naphthalene-2-thione Chemical compound C1=CC=C2C=CC(=S)CC2=C1 QINVNYOGWDNSEP-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- HIGOCZJARKJCGG-UHFFFAOYSA-N 3,4-dihydro-1h-pyrido[2,3-b]pyrazin-2-one Chemical compound C1=CC=C2NC(=O)CNC2=N1 HIGOCZJARKJCGG-UHFFFAOYSA-N 0.000 description 2
- OZEJKXBTUYFTHF-UHFFFAOYSA-N 3-phenyl-3,4-dihydro-1h-pyrido[2,3-b]pyrazin-2-one Chemical compound O=C1NC2=CC=CN=C2NC1C1=CC=CC=C1 OZEJKXBTUYFTHF-UHFFFAOYSA-N 0.000 description 2
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 150000002642 lithium compounds Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- VGNSTKNGRXCJRB-UHFFFAOYSA-N prop-1-en-2-yl 3,6-dimethyl-2-oxo-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound CC1=CC=C2NC(=O)C(C)N(C(=O)OC(C)=C)C2=N1 VGNSTKNGRXCJRB-UHFFFAOYSA-N 0.000 description 2
- UXYGGBNOJOHSTD-UHFFFAOYSA-N propan-2-yl 2-oxo-3-phenyl-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound O=C1NC2=CC=CN=C2N(C(=O)OC(C)C)C1C1=CC=CC=C1 UXYGGBNOJOHSTD-UHFFFAOYSA-N 0.000 description 2
- GSDPADANYSUNOI-UHFFFAOYSA-N propan-2-yl 5-methoxy-2-(methylsulfanylmethyl)-3-oxo-2,4-dihydropyrazino[2,3-d]pyridazine-1-carboxylate Chemical compound CC(C)OC(=O)N1C(CSC)C(=O)NC2=C1C=NN=C2OC GSDPADANYSUNOI-UHFFFAOYSA-N 0.000 description 2
- MKRXCQFWPZANDJ-UHFFFAOYSA-N propan-2-yl 5-methoxy-3-(methylsulfanylmethyl)-2-sulfanylidene-1,3-dihydropyrazino[2,3-d]pyridazine-4-carboxylate Chemical compound N1C(=S)C(CSC)N(C(=O)OC(C)C)C2=C1C=NN=C2OC MKRXCQFWPZANDJ-UHFFFAOYSA-N 0.000 description 2
- 150000004892 pyridazines Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000005987 sulfurization reaction Methods 0.000 description 2
- AZCCYNDIEOBLIV-YFKPBYRVSA-N (3S)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]pyrazin-2-one Chemical compound N1=CC=C2NC(=O)[C@H](C)NC2=C1 AZCCYNDIEOBLIV-YFKPBYRVSA-N 0.000 description 1
- CRVCEKLNTIQYBI-BYPYZUCNSA-N (3s)-6-chloro-3-methyl-3,4-dihydro-1h-pyrido[2,3-b]pyrazin-2-one Chemical compound ClC1=CC=C2NC(=O)[C@H](C)NC2=N1 CRVCEKLNTIQYBI-BYPYZUCNSA-N 0.000 description 1
- GJRCWSBXBPZIRG-VIFPVBQESA-N (3s)-6-chloro-3-methyl-4-(pyridin-2-ylmethyl)-1,3-dihydropyrido[2,3-b]pyrazin-2-one Chemical compound N1([C@H](C(NC2=CC=C(Cl)N=C21)=O)C)CC1=CC=CC=N1 GJRCWSBXBPZIRG-VIFPVBQESA-N 0.000 description 1
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 description 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical group [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- 125000006018 1-methyl-ethenyl group Chemical group 0.000 description 1
- XGXKZNXCORZWLV-UHFFFAOYSA-N 1h-pyrido[3,4-b]pyrazin-2-one Chemical compound N1=CC=C2NC(=O)C=NC2=C1 XGXKZNXCORZWLV-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- MJNNGMNZUQSJNV-UHFFFAOYSA-N 2,4-dihydro-1h-pyrido[3,4-b]pyrazin-3-one Chemical compound C1=NC=C2NC(=O)CNC2=C1 MJNNGMNZUQSJNV-UHFFFAOYSA-N 0.000 description 1
- MHJDKSLZQBDIPG-UHFFFAOYSA-N 2-(2-oxopyrido[2,3-b]pyrazin-1-yl)acetic acid Chemical compound C1=CN=C2N=CC(=O)N(CC(=O)O)C2=C1 MHJDKSLZQBDIPG-UHFFFAOYSA-N 0.000 description 1
- CYBOBNODYVJFNM-UHFFFAOYSA-N 2-amino-2-methylbutanoic acid;hydron;chloride Chemical compound Cl.CCC(C)(N)C(O)=O CYBOBNODYVJFNM-UHFFFAOYSA-N 0.000 description 1
- GLKCOBIIZKYKFN-UHFFFAOYSA-N 2-aminopteridine-4,7-diol Chemical class N1=CC(O)=NC2=NC(N)=NC(O)=C21 GLKCOBIIZKYKFN-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- KDVFRMMRZOCFLS-UHFFFAOYSA-N 2-oxopentanoic acid Chemical compound CCCC(=O)C(O)=O KDVFRMMRZOCFLS-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- ORZSUXQJWMYIFX-UHFFFAOYSA-N 3,6-dimethyl-1h-pyrido[2,3-b]pyrazin-2-one Chemical compound N1C(=O)C(C)=NC2=NC(C)=CC=C21 ORZSUXQJWMYIFX-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- DHVODZREXYLNGL-UHFFFAOYSA-N 3-methyl-1h-pyrido[3,4-b]pyrazin-2-one Chemical compound N1=CC=C2NC(=O)C(C)=NC2=C1 DHVODZREXYLNGL-UHFFFAOYSA-N 0.000 description 1
- WZPZTQIRORXUOQ-UHFFFAOYSA-N 3-methyl-6-(4-methylpiperazin-1-yl)-3,4-dihydro-1h-pyrido[2,3-b]pyrazin-2-one Chemical compound C=1C=C2NC(=O)C(C)NC2=NC=1N1CCN(C)CC1 WZPZTQIRORXUOQ-UHFFFAOYSA-N 0.000 description 1
- SEPQTYODOKLVSB-UHFFFAOYSA-N 3-methylbut-2-enal Chemical compound CC(C)=CC=O SEPQTYODOKLVSB-UHFFFAOYSA-N 0.000 description 1
- PPAULTVPKLVLII-UHFFFAOYSA-N 4,5-diaminopyrimidine Chemical compound NC1=CN=CN=C1N PPAULTVPKLVLII-UHFFFAOYSA-N 0.000 description 1
- KMBOWHJTVQMOEA-UHFFFAOYSA-N 4-acetyl-3-phenyl-1,3-dihydropyrido[2,3-b]pyrazin-2-one Chemical compound O=C1NC2=CC=CN=C2N(C(=O)C)C1C1=CC=CC=C1 KMBOWHJTVQMOEA-UHFFFAOYSA-N 0.000 description 1
- LIPODSDLKCMVON-UHFFFAOYSA-N 4-bromopent-2-ene Chemical compound CC=CC(C)Br LIPODSDLKCMVON-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- DPUUMESTNLIFDE-UHFFFAOYSA-N 4h-pyrido[3,4-b]pyrazin-3-one Chemical compound C1=NC=C2NC(=O)C=NC2=C1 DPUUMESTNLIFDE-UHFFFAOYSA-N 0.000 description 1
- NYCKHFXMMWUDRT-UHFFFAOYSA-N 5-propan-2-ylimidazo[1,5-a]quinoxalin-4-one Chemical class O=C1N(C(C)C)C2=CC=CC=C2N2C1=CN=C2 NYCKHFXMMWUDRT-UHFFFAOYSA-N 0.000 description 1
- ZUPDDKRJOMELAZ-UHFFFAOYSA-N 5h-pteridin-6-one Chemical compound N1=CN=CC2=NC(O)=CN=C21 ZUPDDKRJOMELAZ-UHFFFAOYSA-N 0.000 description 1
- LTHIOQAXEXGEPX-UHFFFAOYSA-N 6,8-dihydro-5h-pteridin-7-one Chemical compound N1=CN=C2NC(=O)CNC2=C1 LTHIOQAXEXGEPX-UHFFFAOYSA-N 0.000 description 1
- FBHURYMJNMGWLK-UHFFFAOYSA-N 6-chloro-3-(methylsulfanylmethyl)-3,4-dihydro-1h-pyrido[2,3-b]pyrazin-2-one Chemical compound ClC1=CC=C2NC(=O)C(CSC)NC2=N1 FBHURYMJNMGWLK-UHFFFAOYSA-N 0.000 description 1
- OHZBBMULIMLOQY-UHFFFAOYSA-N 6-methoxy-3-(methylsulfanylmethyl)-3,4-dihydro-1h-pyrido[2,3-b]pyrazin-2-one Chemical compound N1C(=O)C(CSC)NC2=NC(OC)=CC=C21 OHZBBMULIMLOQY-UHFFFAOYSA-N 0.000 description 1
- AEUGHKKPIVZUBO-UHFFFAOYSA-N 6-methyl-6,8-dihydro-5h-pteridin-7-one Chemical compound N1=CN=C2NC(=O)C(C)NC2=C1 AEUGHKKPIVZUBO-UHFFFAOYSA-N 0.000 description 1
- XATOCNYGIWXIQM-UHFFFAOYSA-N 6-methylpyridine-2,3-diamine Chemical compound CC1=CC=C(N)C(N)=N1 XATOCNYGIWXIQM-UHFFFAOYSA-N 0.000 description 1
- UGYZVBUANICGLW-UHFFFAOYSA-N 7,8-dihydro-5h-pteridin-6-one Chemical compound C1=NC=C2NC(=O)CNC2=N1 UGYZVBUANICGLW-UHFFFAOYSA-N 0.000 description 1
- VLBKSFFDAWLLFB-UHFFFAOYSA-N 7-methyl-7,8-dihydro-5h-pteridin-6-one Chemical compound C1=NC=C2NC(=O)C(C)NC2=N1 VLBKSFFDAWLLFB-UHFFFAOYSA-N 0.000 description 1
- DUGJQFDZSSADIC-UHFFFAOYSA-N 8-amino-2-oxo-3,4,4a,5-tetrahydro-1h-pyrido[2,3-b]pyrazine-7-carboxylic acid Chemical class N1C(=O)CNC2NC=C(C(O)=O)C(N)=C21 DUGJQFDZSSADIC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- RSYKERAQUIKZBX-UHFFFAOYSA-N C1=NC=C2NC(=O)C(CC(=O)OCC)N(C(=O)OC(C)C)C2=C1 Chemical compound C1=NC=C2NC(=O)C(CC(=O)OCC)N(C(=O)OC(C)C)C2=C1 RSYKERAQUIKZBX-UHFFFAOYSA-N 0.000 description 1
- NVTQBAMQXTYZTM-UHFFFAOYSA-N C1=NC=C2NC(=O)C(CSC)N(C(=O)OC(C)=C)C2=C1 Chemical compound C1=NC=C2NC(=O)C(CSC)N(C(=O)OC(C)=C)C2=C1 NVTQBAMQXTYZTM-UHFFFAOYSA-N 0.000 description 1
- QUNVAKGBBWGQCW-UHFFFAOYSA-N C1=NC=C2NC(=S)C(C)(C)N(C(=O)OC(=C)C)C2=N1 Chemical compound C1=NC=C2NC(=S)C(C)(C)N(C(=O)OC(=C)C)C2=N1 QUNVAKGBBWGQCW-UHFFFAOYSA-N 0.000 description 1
- QFYGFUNMXNNZSS-UHFFFAOYSA-N C1=NC=C2NC(=S)C(CSC)N(C(=O)OC(C)=C)C2=C1 Chemical compound C1=NC=C2NC(=S)C(CSC)N(C(=O)OC(C)=C)C2=C1 QFYGFUNMXNNZSS-UHFFFAOYSA-N 0.000 description 1
- YMMJYQBKSHGXSJ-UHFFFAOYSA-N C1=NC=C2NC(=S)C(CSC)N(C(=O)OC(C)C)C2=N1 Chemical compound C1=NC=C2NC(=S)C(CSC)N(C(=O)OC(C)C)C2=N1 YMMJYQBKSHGXSJ-UHFFFAOYSA-N 0.000 description 1
- WAZCHLYDTYFXFC-UHFFFAOYSA-N ClC1=NC=C2NC(=S)C(CSC)N(C(=O)OC(C)C)C2=N1 Chemical compound ClC1=NC=C2NC(=S)C(CSC)N(C(=O)OC(C)C)C2=N1 WAZCHLYDTYFXFC-UHFFFAOYSA-N 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- DYHQILQPXGBZKY-UHFFFAOYSA-N N1=CN=C2NC(=O)C(C)(C)N(C(=O)OC(=C)C)C2=C1 Chemical compound N1=CN=C2NC(=O)C(C)(C)N(C(=O)OC(=C)C)C2=C1 DYHQILQPXGBZKY-UHFFFAOYSA-N 0.000 description 1
- FXFKWEQVEIXGHQ-UHFFFAOYSA-N N1=CN=C2NC(=O)C(CSC)N(C(=O)OC(C)C)C2=C1 Chemical compound N1=CN=C2NC(=O)C(CSC)N(C(=O)OC(C)C)C2=C1 FXFKWEQVEIXGHQ-UHFFFAOYSA-N 0.000 description 1
- DYQBGPGXYVWGDZ-UHFFFAOYSA-N N1C(=O)C(C)N(C(=O)OC(C)=C)C2=NC(OC)=NC=C21 Chemical compound N1C(=O)C(C)N(C(=O)OC(C)=C)C2=NC(OC)=NC=C21 DYQBGPGXYVWGDZ-UHFFFAOYSA-N 0.000 description 1
- YGNFQMGNKFVPNY-UHFFFAOYSA-N N1C(=S)C(CSC)N(C(=O)OC(C)C)C2=NC(OC)=NC=C21 Chemical compound N1C(=S)C(CSC)N(C(=O)OC(C)C)C2=NC(OC)=NC=C21 YGNFQMGNKFVPNY-UHFFFAOYSA-N 0.000 description 1
- HFBPCGKGOGDVOH-UHFFFAOYSA-N NC1=NC=C2NC(=O)C(C)N(C(=O)OC(C)=C)C2=N1 Chemical compound NC1=NC=C2NC(=O)C(C)N(C(=O)OC(C)=C)C2=N1 HFBPCGKGOGDVOH-UHFFFAOYSA-N 0.000 description 1
- UMHVAASGSPULAV-UHFFFAOYSA-N NC1=NC=C2NC(=S)C(C)N(C(=O)OC(C)=C)C2=N1 Chemical compound NC1=NC=C2NC(=S)C(C)N(C(=O)OC(C)=C)C2=N1 UMHVAASGSPULAV-UHFFFAOYSA-N 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- DZGGQYRMTMIMOU-UHFFFAOYSA-N S=C1NC2=CC=CN=C2N(C(=O)OC(C)C)C1C1=C(Cl)C=CC=C1Cl Chemical compound S=C1NC2=CC=CN=C2N(C(=O)OC(C)C)C1C1=C(Cl)C=CC=C1Cl DZGGQYRMTMIMOU-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000006359 acetalization reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000001343 alkyl silanes Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- RLECCBFNWDXKPK-UHFFFAOYSA-N bis(trimethylsilyl)sulfide Chemical compound C[Si](C)(C)S[Si](C)(C)C RLECCBFNWDXKPK-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000006459 hydrosilylation reaction Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006629 isopropoxycarbonylamino group Chemical group 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- BHFLUDRTVIDDOR-MRVPVSSYSA-N methyl (2r)-2-amino-2-phenylacetate Chemical compound COC(=O)[C@H](N)C1=CC=CC=C1 BHFLUDRTVIDDOR-MRVPVSSYSA-N 0.000 description 1
- OMBVLJSHPJLTKD-BYPYZUCNSA-N methyl (2r)-2-amino-3-methylsulfanylpropanoate Chemical compound COC(=O)[C@@H](N)CSC OMBVLJSHPJLTKD-BYPYZUCNSA-N 0.000 description 1
- KTMOZZKFOZPLBJ-QMMMGPOBSA-N methyl (2s)-2-(pyridin-2-ylmethylamino)propanoate Chemical compound COC(=O)[C@H](C)NCC1=CC=CC=N1 KTMOZZKFOZPLBJ-QMMMGPOBSA-N 0.000 description 1
- QEJGUCIALDACCS-YFKPBYRVSA-N methyl (2s)-2-[(6-chloro-3-nitropyridin-2-yl)amino]propanoate Chemical compound COC(=O)[C@H](C)NC1=NC(Cl)=CC=C1[N+]([O-])=O QEJGUCIALDACCS-YFKPBYRVSA-N 0.000 description 1
- BHFLUDRTVIDDOR-QMMMGPOBSA-N methyl (2s)-2-amino-2-phenylacetate Chemical compound COC(=O)[C@@H](N)C1=CC=CC=C1 BHFLUDRTVIDDOR-QMMMGPOBSA-N 0.000 description 1
- IYUKFAFDFHZKPI-DFWYDOINSA-N methyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](C)N IYUKFAFDFHZKPI-DFWYDOINSA-N 0.000 description 1
- MAQULIULLOBHGK-UHFFFAOYSA-N methyl 2-(methylamino)-2-phenylacetate Chemical compound COC(=O)C(NC)C1=CC=CC=C1 MAQULIULLOBHGK-UHFFFAOYSA-N 0.000 description 1
- IXEBRVGOAZDAHN-UHFFFAOYSA-N methyl 2-[(6-chloro-3-nitropyridin-2-yl)amino]-2-methylpropanoate Chemical compound COC(=O)C(C)(C)NC1=NC(Cl)=CC=C1[N+]([O-])=O IXEBRVGOAZDAHN-UHFFFAOYSA-N 0.000 description 1
- SQGLAIFTDOIHOC-UHFFFAOYSA-N methyl 2-[(6-methoxy-3-nitropyridin-2-yl)amino]-2-methylpropanoate Chemical compound COC(=O)C(C)(C)NC1=NC(OC)=CC=C1[N+]([O-])=O SQGLAIFTDOIHOC-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- REGHGGIABPLKTK-UHFFFAOYSA-N prop-1-en-2-yl 2-amino-7,7-dimethyl-6-oxo-5h-pteridine-8-carboxylate Chemical compound NC1=NC=C2NC(=O)C(C)(C)N(C(=O)OC(=C)C)C2=N1 REGHGGIABPLKTK-UHFFFAOYSA-N 0.000 description 1
- UWGYXNGNYVMPQQ-UHFFFAOYSA-N prop-1-en-2-yl 2-methoxy-7,7-dimethyl-6-oxo-5h-pteridine-8-carboxylate Chemical compound N1C(=O)C(C)(C)N(C(=O)OC(C)=C)C2=NC(OC)=NC=C21 UWGYXNGNYVMPQQ-UHFFFAOYSA-N 0.000 description 1
- RXGHAJYDTOGFKI-UHFFFAOYSA-N prop-1-en-2-yl 2-methoxy-7,7-dimethyl-6-sulfanylidene-5h-pteridine-8-carboxylate Chemical compound N1C(=S)C(C)(C)N(C(=O)OC(C)=C)C2=NC(OC)=NC=C21 RXGHAJYDTOGFKI-UHFFFAOYSA-N 0.000 description 1
- VMGJOBSIJYERNQ-UHFFFAOYSA-N prop-1-en-2-yl 2-methoxy-7-methyl-6-sulfanylidene-5,7-dihydropteridine-8-carboxylate Chemical compound N1C(=S)C(C)N(C(=O)OC(C)=C)C2=NC(OC)=NC=C21 VMGJOBSIJYERNQ-UHFFFAOYSA-N 0.000 description 1
- XHRXUENPBFXVJI-UHFFFAOYSA-N prop-1-en-2-yl 2-oxo-3-phenyl-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound O=C1NC2=CC=CN=C2N(C(=O)OC(=C)C)C1C1=CC=CC=C1 XHRXUENPBFXVJI-UHFFFAOYSA-N 0.000 description 1
- ZOTNDAFZKNKZLT-UHFFFAOYSA-N prop-1-en-2-yl 3,6-dimethyl-2-sulfanylidene-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound CC1=CC=C2NC(=S)C(C)N(C(=O)OC(C)=C)C2=N1 ZOTNDAFZKNKZLT-UHFFFAOYSA-N 0.000 description 1
- PSWAZBPRPDPDKM-UHFFFAOYSA-N prop-1-en-2-yl 3-(2,6-dichlorophenyl)-2-sulfanylidene-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound S=C1NC2=CC=CN=C2N(C(=O)OC(=C)C)C1C1=C(Cl)C=CC=C1Cl PSWAZBPRPDPDKM-UHFFFAOYSA-N 0.000 description 1
- UNFQPHYKBMLNRJ-UHFFFAOYSA-N prop-1-en-2-yl 3-methyl-2-oxo-3,4-dihydropyrido[2,3-b]pyrazine-1-carboxylate Chemical compound C(=C)(C)OC(=O)N1C(C(NC2=NC=CC=C12)C)=O UNFQPHYKBMLNRJ-UHFFFAOYSA-N 0.000 description 1
- LYVPUWOUJAFDRM-UHFFFAOYSA-N prop-1-en-2-yl 3-phenyl-2-sulfanylidene-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound S=C1NC2=CC=CN=C2N(C(=O)OC(=C)C)C1C1=CC=CC=C1 LYVPUWOUJAFDRM-UHFFFAOYSA-N 0.000 description 1
- OZUCXMLSOGLANX-UHFFFAOYSA-N prop-1-en-2-yl 6,6-dimethyl-7-sulfanylidene-8h-pteridine-5-carboxylate Chemical compound N1=CN=C2NC(=S)C(C)(C)N(C(=O)OC(=C)C)C2=C1 OZUCXMLSOGLANX-UHFFFAOYSA-N 0.000 description 1
- DVRHKGNRNFWLOX-UHFFFAOYSA-N prop-1-en-2-yl 6-chloro-2-oxo-3-phenyl-3,4-dihydropyrido[2,3-b]pyrazine-1-carboxylate Chemical compound N1C2=NC(Cl)=CC=C2N(C(=O)OC(=C)C)C(=O)C1C1=CC=CC=C1 DVRHKGNRNFWLOX-UHFFFAOYSA-N 0.000 description 1
- WPQIOKJQDDPESV-UHFFFAOYSA-N prop-1-en-2-yl 6-chloro-3,3-dimethyl-2-oxo-1h-pyrido[2,3-b]pyrazine-4-carboxylate Chemical compound ClC1=CC=C2NC(=O)C(C)(C)N(C(=O)OC(=C)C)C2=N1 WPQIOKJQDDPESV-UHFFFAOYSA-N 0.000 description 1
- RCPNPUNQQUUWIA-UHFFFAOYSA-N prop-1-en-2-yl 6-chloro-3-(methylsulfanylmethyl)-2-oxo-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound ClC1=CC=C2NC(=O)C(CSC)N(C(=O)OC(C)=C)C2=N1 RCPNPUNQQUUWIA-UHFFFAOYSA-N 0.000 description 1
- RBCBOYYADQGDHH-UHFFFAOYSA-N prop-1-en-2-yl 6-chloro-3-(methylsulfanylmethyl)-2-sulfanylidene-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound ClC1=CC=C2NC(=S)C(CSC)N(C(=O)OC(C)=C)C2=N1 RBCBOYYADQGDHH-UHFFFAOYSA-N 0.000 description 1
- VVIMYUSXTVXCIZ-UHFFFAOYSA-N prop-1-en-2-yl 6-methoxy-3,3-dimethyl-2-oxo-1h-pyrido[2,3-b]pyrazine-4-carboxylate Chemical compound N1C(=O)C(C)(C)N(C(=O)OC(C)=C)C2=NC(OC)=CC=C21 VVIMYUSXTVXCIZ-UHFFFAOYSA-N 0.000 description 1
- KJQYDTFLHKSJSP-UHFFFAOYSA-N prop-1-en-2-yl 6-methyl-7-oxo-6,8-dihydropteridine-5-carboxylate Chemical compound N1=CN=C2NC(=O)C(C)N(C(=O)OC(C)=C)C2=C1 KJQYDTFLHKSJSP-UHFFFAOYSA-N 0.000 description 1
- FYDFQDPHWMKQLK-UHFFFAOYSA-N prop-1-en-2-yl 6-methyl-7-sulfanylidene-6,8-dihydropteridine-5-carboxylate Chemical compound N1=CN=C2NC(=S)C(C)N(C(=O)OC(C)=C)C2=C1 FYDFQDPHWMKQLK-UHFFFAOYSA-N 0.000 description 1
- POKFIULVZNWRNS-UHFFFAOYSA-N prop-1-en-2-yl 7,7-dimethyl-6-oxo-5h-pteridine-8-carboxylate Chemical compound C1=NC=C2NC(=O)C(C)(C)N(C(=O)OC(=C)C)C2=N1 POKFIULVZNWRNS-UHFFFAOYSA-N 0.000 description 1
- GZMFFSVZQYQAHG-UHFFFAOYSA-N prop-1-en-2-yl 7-methyl-6-oxo-5,7-dihydropteridine-8-carboxylate Chemical compound C1=NC=C2NC(=O)C(C)N(C(=O)OC(C)=C)C2=N1 GZMFFSVZQYQAHG-UHFFFAOYSA-N 0.000 description 1
- AMMGCGVWJMRTQI-UHFFFAOYSA-N prop-1-en-2-yl carbonochloridate Chemical compound CC(=C)OC(Cl)=O AMMGCGVWJMRTQI-UHFFFAOYSA-N 0.000 description 1
- YODXTVVGNOHXOK-UHFFFAOYSA-N prop-1-enyl carbonochloridate Chemical compound CC=COC(Cl)=O YODXTVVGNOHXOK-UHFFFAOYSA-N 0.000 description 1
- RCMCQWIUWWSUAN-UHFFFAOYSA-N propan-2-yl 2-(methylsulfanylmethyl)-3-sulfanylidene-2,4-dihydropyrido[3,4-b]pyrazine-1-carboxylate Chemical compound C1=NC=C2NC(=S)C(CSC)N(C(=O)OC(C)C)C2=C1 RCMCQWIUWWSUAN-UHFFFAOYSA-N 0.000 description 1
- YFPJRSOEWKGHHF-UHFFFAOYSA-N propan-2-yl 2-amino-7-(methylsulfanylmethyl)-6-oxo-5,7-dihydropteridine-8-carboxylate Chemical compound NC1=NC=C2NC(=O)C(CSC)N(C(=O)OC(C)C)C2=N1 YFPJRSOEWKGHHF-UHFFFAOYSA-N 0.000 description 1
- DPDYLFNGRPCXCA-UHFFFAOYSA-N propan-2-yl 2-amino-7-(methylsulfanylmethyl)-6-sulfanylidene-5,7-dihydropteridine-8-carboxylate Chemical compound NC1=NC=C2NC(=S)C(CSC)N(C(=O)OC(C)C)C2=N1 DPDYLFNGRPCXCA-UHFFFAOYSA-N 0.000 description 1
- FCVLVYOWCMCFHI-UHFFFAOYSA-N propan-2-yl 2-chloro-7-(methylsulfanylmethyl)-6-oxo-5,7-dihydropteridine-8-carboxylate Chemical compound ClC1=NC=C2NC(=O)C(CSC)N(C(=O)OC(C)C)C2=N1 FCVLVYOWCMCFHI-UHFFFAOYSA-N 0.000 description 1
- FLXOKBBFVLQVQY-UHFFFAOYSA-N propan-2-yl 2-methoxy-7-(methylsulfanylmethyl)-6-oxo-5,7-dihydropteridine-8-carboxylate Chemical compound N1C(=O)C(CSC)N(C(=O)OC(C)C)C2=NC(OC)=NC=C21 FLXOKBBFVLQVQY-UHFFFAOYSA-N 0.000 description 1
- HHIUFBCMNRGIKO-UHFFFAOYSA-N propan-2-yl 3-(2-ethoxy-2-oxoethyl)-2-oxo-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound C1=CC=C2NC(=O)C(CC(=O)OCC)N(C(=O)OC(C)C)C2=N1 HHIUFBCMNRGIKO-UHFFFAOYSA-N 0.000 description 1
- RUDOEPZHGRAHLZ-UHFFFAOYSA-N propan-2-yl 3-(methylsulfanylmethyl)-2-oxo-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound C1=CC=C2NC(=O)C(CSC)N(C(=O)OC(C)C)C2=N1 RUDOEPZHGRAHLZ-UHFFFAOYSA-N 0.000 description 1
- USJPVYMJCTYNTK-UHFFFAOYSA-N propan-2-yl 5-chloro-2-(methylsulfanylmethyl)-3-oxo-2,4-dihydropyrazino[2,3-d]pyridazine-1-carboxylate Chemical compound N1=NC(Cl)=C2NC(=O)C(CSC)N(C(=O)OC(C)C)C2=C1 USJPVYMJCTYNTK-UHFFFAOYSA-N 0.000 description 1
- NOJCAIIFAQUIKS-UHFFFAOYSA-N propan-2-yl 5-chloro-2-(methylsulfanylmethyl)-3-sulfanylidene-2,4-dihydropyrazino[2,3-d]pyridazine-1-carboxylate Chemical compound N1=NC(Cl)=C2NC(=S)C(CSC)N(C(=O)OC(C)C)C2=C1 NOJCAIIFAQUIKS-UHFFFAOYSA-N 0.000 description 1
- LDPWSXQHVKNXLZ-UHFFFAOYSA-N propan-2-yl 5-methoxy-2-(methylsulfanylmethyl)-3-sulfanylidene-2,4-dihydropyrazino[2,3-d]pyridazine-1-carboxylate Chemical compound CC(C)OC(=O)N1C(CSC)C(=S)NC2=C1C=NN=C2OC LDPWSXQHVKNXLZ-UHFFFAOYSA-N 0.000 description 1
- GMYHCJAQDDAZBW-UHFFFAOYSA-N propan-2-yl 5-methoxy-3-(methylsulfanylmethyl)-2-oxo-1,3-dihydropyrazino[2,3-d]pyridazine-4-carboxylate Chemical compound N1C(=O)C(CSC)N(C(=O)OC(C)C)C2=C1C=NN=C2OC GMYHCJAQDDAZBW-UHFFFAOYSA-N 0.000 description 1
- HMWPVNOXKHFNCK-UHFFFAOYSA-N propan-2-yl 6-chloro-3-(methylsulfanylmethyl)-2-oxo-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound ClC1=CC=C2NC(=O)C(CSC)N(C(=O)OC(C)C)C2=N1 HMWPVNOXKHFNCK-UHFFFAOYSA-N 0.000 description 1
- HMGCJULSHBUQJJ-UHFFFAOYSA-N propan-2-yl 6-chloro-3-(methylsulfanylmethyl)-2-sulfanylidene-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound ClC1=CC=C2NC(=S)C(CSC)N(C(=O)OC(C)C)C2=N1 HMGCJULSHBUQJJ-UHFFFAOYSA-N 0.000 description 1
- WNLFRQFWQBREPR-UHFFFAOYSA-N propan-2-yl 6-methoxy-3-(methylsulfanylmethyl)-2-oxo-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound N1C(=O)C(CSC)N(C(=O)OC(C)C)C2=NC(OC)=CC=C21 WNLFRQFWQBREPR-UHFFFAOYSA-N 0.000 description 1
- KDXPODRGWFEAQO-UHFFFAOYSA-N propan-2-yl 6-methoxy-3-(methylsulfanylmethyl)-2-sulfanylidene-1,3-dihydropyrido[2,3-b]pyrazine-4-carboxylate Chemical compound N1C(=S)C(CSC)N(C(=O)OC(C)C)C2=NC(OC)=CC=C21 KDXPODRGWFEAQO-UHFFFAOYSA-N 0.000 description 1
- KHPKSSZUBKYZTO-UHFFFAOYSA-N propan-2-yl 6-methyl-7-sulfanylidene-6,8-dihydropteridine-5-carboxylate Chemical compound C1=NC=C2N(C(=O)OC(C)C)C(C)C(=S)NC2=N1 KHPKSSZUBKYZTO-UHFFFAOYSA-N 0.000 description 1
- NOWBJNCZDZHCSF-UHFFFAOYSA-N propan-2-yl 7-(methylsulfanylmethyl)-6-oxo-5,7-dihydropteridine-8-carboxylate Chemical compound C1=NC=C2NC(=O)C(CSC)N(C(=O)OC(C)C)C2=N1 NOWBJNCZDZHCSF-UHFFFAOYSA-N 0.000 description 1
- PQFITNDZYJXOFI-UHFFFAOYSA-N propan-2-yl 7-methyl-6-sulfanylidene-5,7-dihydropteridine-8-carboxylate Chemical compound N1=CN=C2N(C(=O)OC(C)C)C(C)C(=S)NC2=C1 PQFITNDZYJXOFI-UHFFFAOYSA-N 0.000 description 1
- YCSWRJRYPVDVEZ-UHFFFAOYSA-N propan-2-yl n-[3-methyl-4-(2-methylpropanoyl)-2-oxo-1,3-dihydropyrido[2,3-b]pyrazin-6-yl]-n-propylcarbamate Chemical compound N1C(=O)C(C)N(C(=O)C(C)C)C2=NC(N(C(=O)OC(C)C)CCC)=CC=C21 YCSWRJRYPVDVEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- OUFHXMSGJIYFPW-UHFFFAOYSA-N pyrazino[2,3-c]pyridazine Chemical class N1=NC=CC2=NC=CN=C21 OUFHXMSGJIYFPW-UHFFFAOYSA-N 0.000 description 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical class N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- NBTHYJWPOYZDHL-UHFFFAOYSA-N tricyclohexyl(tricyclohexylstannylsulfanyl)stannane Chemical compound C1CCCCC1[Sn](C1CCCCC1)(C1CCCCC1)S[Sn](C1CCCCC1)(C1CCCCC1)C1CCCCC1 NBTHYJWPOYZDHL-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- NTCQOKPUDSWFJF-UHFFFAOYSA-N triphenyl(triphenylstannylsulfanyl)stannane Chemical compound C=1C=CC=CC=1[Sn](C=1C=CC=CC=1)(C=1C=CC=CC=1)S[Sn](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 NTCQOKPUDSWFJF-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- VURKRJGMSKJIQX-UHFFFAOYSA-N xanthopterin Chemical class N1C(=O)C=NC2=C1C(=O)N=C(N)N2 VURKRJGMSKJIQX-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Radar Systems Or Details Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4232392 | 1992-09-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HU9302696D0 HU9302696D0 (en) | 1993-12-28 |
| HUT65302A true HUT65302A (en) | 1994-05-02 |
Family
ID=6468974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9302696A HUT65302A (en) | 1992-09-26 | 1993-09-24 | Azaquinoxaline- derivatives with antiviral effect and process for the production of these compounds and of pharmaceutical preparatives containing it |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5424311A (enExample) |
| EP (1) | EP0590428B1 (enExample) |
| JP (1) | JPH06211855A (enExample) |
| KR (1) | KR940007035A (enExample) |
| AT (1) | ATE187724T1 (enExample) |
| AU (1) | AU664643B2 (enExample) |
| CA (1) | CA2106882C (enExample) |
| CZ (1) | CZ9302005A3 (enExample) |
| DE (1) | DE59309902D1 (enExample) |
| DK (1) | DK0590428T3 (enExample) |
| ES (1) | ES2141744T3 (enExample) |
| GR (1) | GR3032520T3 (enExample) |
| HU (1) | HUT65302A (enExample) |
| IL (1) | IL107081A (enExample) |
| MX (1) | MX9305894A (enExample) |
| NZ (1) | NZ248762A (enExample) |
| PH (1) | PH30348A (enExample) |
| PT (1) | PT590428E (enExample) |
| TW (1) | TW274550B (enExample) |
| ZA (1) | ZA937081B (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995018616A2 (en) * | 1994-01-03 | 1995-07-13 | Acea Pharm Inc | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |
| US5801183A (en) * | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
| US5646130A (en) * | 1995-06-30 | 1997-07-08 | Ocean University Of Oingdao | Low molecular weight sulfated polysaccharides and uses thereof |
| ZA973884B (en) * | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| CA2313789A1 (en) | 1998-07-16 | 2000-01-27 | Aaron Tabor | Soy formulations and their use for promoting health |
| US6930101B1 (en) | 1999-05-17 | 2005-08-16 | The Regents Of The University Of California | Thiazolopyrimidines useful as TNFα inhibitors |
| US7101883B2 (en) | 2002-03-18 | 2006-09-05 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases |
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE10323345A1 (de) * | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| AU2004240747B2 (en) * | 2003-05-23 | 2008-01-03 | Zentaris Gmbh | Novel pyridopyrazines and use thereof as kinase modulators |
| MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| RS51885B (sr) * | 2006-04-21 | 2012-02-29 | Pfizer Products Inc. | PIRIDIN[3,4-b] PIRAZINONI |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| GB0614471D0 (en) * | 2006-07-20 | 2006-08-30 | Syngenta Ltd | Herbicidal Compounds |
| RU2478635C2 (ru) * | 2006-10-19 | 2013-04-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений |
| KR101451290B1 (ko) * | 2006-10-19 | 2014-10-15 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
| WO2008063455A1 (en) * | 2006-11-13 | 2008-05-29 | Hines Richard A | Over-the wire exclusion device and system for delivery |
| WO2009019205A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| SG172060A1 (en) * | 2008-12-09 | 2011-07-28 | Gilead Sciences Inc | Modulators of toll-like receptors |
| EP2389379A1 (en) | 2009-01-23 | 2011-11-30 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| JP5715625B2 (ja) | 2009-07-30 | 2015-05-07 | 武田薬品工業株式会社 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 |
| AU2010292102B2 (en) * | 2009-09-14 | 2015-04-09 | Gilead Sciences, Inc. | Modulators of Toll-like receptors |
| CN106117213B (zh) * | 2009-10-26 | 2022-03-18 | 西格诺药品有限公司 | 杂芳基化合物及其合成和纯化方法 |
| AR080643A1 (es) | 2010-02-03 | 2012-04-25 | Signal Pharm Llc | Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| TWI713752B (zh) | 2011-10-19 | 2020-12-21 | 標誌製藥公司 | 以ｔｏｒ激酶抑制劑治療癌症 |
| EP2776444A4 (en) | 2011-11-10 | 2015-07-22 | Osi Pharmaceuticals Llc | dihydropteridinones |
| US9403829B2 (en) | 2011-12-02 | 2016-08-02 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| EP2817029B1 (en) | 2012-02-24 | 2019-07-10 | Signal Pharmaceuticals, LLC | Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| CN105188704B (zh) | 2013-01-16 | 2017-09-19 | 西格诺药品有限公司 | 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法 |
| CN105392499B (zh) | 2013-04-17 | 2018-07-24 | 西格诺药品有限公司 | 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法 |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
| BR112015026292B1 (pt) | 2013-04-17 | 2022-04-12 | Signal Pharmaceuticals, Llc | Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro |
| BR112015026021A2 (pt) | 2013-04-17 | 2017-07-25 | Signal Pharm Llc | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer |
| EA030726B1 (ru) | 2013-04-17 | 2018-09-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ |
| CN113730412A (zh) | 2013-04-17 | 2021-12-03 | 西格诺药品有限公司 | 用二氢吡嗪并-吡嗪治疗癌症 |
| MX2015015880A (es) | 2013-05-29 | 2016-05-31 | Signal Pharm Llc | Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida del mismo y metodos de su uso. |
| US20150031699A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| CN113577081A (zh) | 2014-07-11 | 2021-11-02 | 吉利德科学公司 | 用于治疗hiv的toll样受体调节剂 |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
| ES2845205T3 (es) | 2014-09-16 | 2021-07-26 | Gilead Sciences Inc | Métodos para preparar moduladores de receptores tipo Toll |
| UY36298A (es) | 2014-09-16 | 2016-04-29 | Gilead Science Inc | Formas sólidas de un modulador del receptor tipo toll |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| MY198676A (en) | 2017-06-22 | 2023-09-15 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| KR102272284B1 (ko) * | 2020-01-13 | 2021-07-02 | 금오공과대학교 산학협력단 | 정밀 압력제어가 가능한 다단 스프링 압력제어밸브 |
| TW202523312A (zh) * | 2023-10-16 | 2025-06-16 | 美商克洛諾斯生技有限公司 | 離胺酸乙醯基轉移酶抑制劑 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4077955A (en) * | 1977-02-17 | 1978-03-07 | E. R. Squibb & Sons, Inc. | Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters |
| PH15791A (en) * | 1978-10-20 | 1983-03-25 | Lilly Co Eli | Pharmaceutical composition containing 3,4-dihydro-3-oxoquinoxalines |
| IE58312B1 (en) * | 1984-05-18 | 1993-09-08 | Union Pharma Scient Appl | Heterocyclic derivatives, processes for their preparation and drugs in which they are present, which are useful especially as aldose reductase inhibitors |
| JPH0276860A (ja) * | 1987-10-05 | 1990-03-16 | Toyo Jozo Co Ltd | ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体 |
| DK160876C (da) * | 1987-12-08 | 1991-10-14 | Novo Nordisk As | Imidazoquinoxalinforbindelser, fremgangsmaade til deres fremstilling, anvendelse af forbindelserne og farmaceutiske praeparater, hvori forbindelserne indgaar |
| EP0509398B1 (de) * | 1991-04-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung |
-
1993
- 1993-09-09 TW TW082107380A patent/TW274550B/zh active
- 1993-09-16 DK DK93114934T patent/DK0590428T3/da active
- 1993-09-16 DE DE59309902T patent/DE59309902D1/de not_active Expired - Fee Related
- 1993-09-16 EP EP93114934A patent/EP0590428B1/de not_active Expired - Lifetime
- 1993-09-16 ES ES93114934T patent/ES2141744T3/es not_active Expired - Lifetime
- 1993-09-16 AT AT93114934T patent/ATE187724T1/de not_active IP Right Cessation
- 1993-09-16 PT PT93114934T patent/PT590428E/pt unknown
- 1993-09-23 AU AU47553/93A patent/AU664643B2/en not_active Ceased
- 1993-09-23 IL IL10708193A patent/IL107081A/en not_active IP Right Cessation
- 1993-09-23 US US08/125,163 patent/US5424311A/en not_active Expired - Lifetime
- 1993-09-24 CZ CZ932005A patent/CZ9302005A3/cs unknown
- 1993-09-24 CA CA002106882A patent/CA2106882C/en not_active Expired - Fee Related
- 1993-09-24 HU HU9302696A patent/HUT65302A/hu unknown
- 1993-09-24 NZ NZ248762A patent/NZ248762A/en unknown
- 1993-09-24 JP JP5237679A patent/JPH06211855A/ja active Pending
- 1993-09-24 ZA ZA937081A patent/ZA937081B/xx unknown
- 1993-09-24 PH PH46948A patent/PH30348A/en unknown
- 1993-09-24 MX MX9305894A patent/MX9305894A/es not_active IP Right Cessation
- 1993-09-25 KR KR1019930019733A patent/KR940007035A/ko not_active Withdrawn
-
2000
- 2000-01-31 GR GR20000400216T patent/GR3032520T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA937081B (en) | 1994-04-18 |
| IL107081A (en) | 1999-07-14 |
| EP0590428B1 (de) | 1999-12-15 |
| HU9302696D0 (en) | 1993-12-28 |
| MX9305894A (es) | 1994-03-31 |
| JPH06211855A (ja) | 1994-08-02 |
| IL107081A0 (en) | 1993-12-28 |
| TW274550B (enExample) | 1996-04-21 |
| US5424311A (en) | 1995-06-13 |
| KR940007035A (ko) | 1994-04-26 |
| CZ9302005A3 (en) | 1994-04-13 |
| EP0590428A1 (de) | 1994-04-06 |
| CA2106882C (en) | 2007-04-17 |
| GR3032520T3 (en) | 2000-05-31 |
| PH30348A (en) | 1997-04-02 |
| DE59309902D1 (de) | 2000-01-20 |
| PT590428E (pt) | 2000-04-28 |
| AU4755393A (en) | 1994-03-31 |
| AU664643B2 (en) | 1995-11-23 |
| ATE187724T1 (de) | 2000-01-15 |
| ES2141744T3 (es) | 2000-04-01 |
| NZ248762A (en) | 1996-01-26 |
| CA2106882A1 (en) | 1994-03-27 |
| DK0590428T3 (da) | 2000-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUT65302A (en) | Azaquinoxaline- derivatives with antiviral effect and process for the production of these compounds and of pharmaceutical preparatives containing it | |
| EP2415767B1 (en) | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | |
| EP1343780B1 (en) | Piperazine derivatives for treatment of bacterial infections | |
| US20070179165A1 (en) | Cyclic compounds | |
| JPH11504922A (ja) | 蛋白チロシンキナーゼ媒介細胞増殖を抑制するためのピリド［２，３−ｄ］ピリミジン類 | |
| KR100245138B1 (ko) | 퀴녹살린,이의 제조방법 및 이를 함유하는 약제학적 조성물 | |
| AU1081700A (en) | Pyrazolopyrimidinone derivatives for the treatment of impotence | |
| HU193754B (en) | Process for preparing pyrrolo-benzimidazoles | |
| HU207068B (en) | Process for producing thiadiazone derivatives and pharmaceutical compositions comprising same | |
| US20030187257A1 (en) | Triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-one derivatives | |
| US6369057B1 (en) | Quinoxalines, processes for their preparation and their use | |
| NZ539598A (en) | Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same | |
| US20020006380A1 (en) | Pyrrole derivatives, their preparation and pharmaceutical compositions containing them | |
| US6114349A (en) | Substituted quinoline derivatives with antiviral action | |
| NZ280258A (en) | Quinoxaline derivatives; preparative method and medicaments | |
| JP3605123B2 (ja) | ４−イミノキノリン、その製法およびそれを含有する抗ウイルス剤 | |
| JPH0859621A (ja) | 置換キノリン誘導体、それらの製造方法およびそれらの使用 | |
| CS220343B2 (en) | Method of producing new imidazoquinazoline derivatives | |
| EP0511792A2 (en) | Pyridoprimidine derivatives as antineoplastic agents | |
| A Ghoneim et al. | Synthesis of some new chromeno [2, 3-b] pyridine and [1, 2, 4] triazolo [1, 5-a] quinoline nucleoside analogues with expected biological activity | |
| US6525063B2 (en) | Antitumour 1,5-diazaanthraquinones | |
| US6949652B2 (en) | Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine | |
| US4451650A (en) | Pyrido[4,3-b][1,4]oxazines and pyrido[4,3-b][1,4]thiazines | |
| EP1806348A2 (en) | Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DFA9 | Temporary protection cancelled due to abandonment |